MedTrace Logo

IW-6463 Safety Study in Healthy Elderly Subjects

NCT04240158 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-08-16

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, 2-way cross-over study in healthy male and female elderly participants.

Conditions

  • Other

Interventions

DRUG

IW-6463

IW-6463 Tablet

DRUG

Matching Placebo

Matching Placebo Tablet

Sponsors & Collaborators

  • Tisento Therapeutics

    lead INDUSTRY

Principal Investigators

  • Chad Glasser, PharmD · Cyclerion Therapeutics, Inc

  • Geert Jan Groeneveld, MSc · Centre for Human Drug Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-06
Primary Completion
2020-05-22
Completion
2020-05-22
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04240158 on ClinicalTrials.gov